Anti-Myosin-9/MYH9 Antibody, clone 3O13 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 3O13 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Mysosin-9 (MYH9). It targets an epitope within 16 amino acids from the C-terminal region.

KLH-conjugated linear peptide corresponding to 16 amino acids from the C-terminal region of human Myosin-9 (MYH9).

Quality Control Testing

Evaluated by Immunohistochemistry (Paraffin) in Human kidney tissue sections.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution of this antibody detected Myosin-9/MYH9 in Human kidney tissue sections.

Tested Applications

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected Myosin-9/MYH9 in C2C12 cells.

Affinity Binding Assay: A representative lot of this antibody bound Myosin-9 peptide with a KD of 2.1 x 10-8 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Myosin-9 (UniProt: P35579; also known as Cellular myosin heavy chain type A, Myosin heavy chain 9, Myosin heavy chain non-muscle IIa, Non-muscle myosin heavy chain A, NMMHC-A, Non-muscle myosin heavy chain IIa, NMMHC II-a, NMMHC-IIA) is encoded by the MYH9 gene (Gene ID: 4627) in human. Myosins are highly conserved, ubiquitously expressed proteins that form regular bipolar thick filaments that together with actin thin filaments constitute the fundamental contractile unit of skeletal and cardiac muscle. Along with actin they serve as motor molecules with ATPase activity that is essential for muscle contraction. Myosin consists of 2 heavy chain subunits (MHC), 2 light chain subunits (MLC) and 2 regulatory light chain subunits (MLC-2). MLC-2C plays an important role in regulation of both smooth muscle and non-muscle cell contractile activity via its phosphorylation. Myosin-9 is a cellular myosin that is expressed in kidney and leukocytes. Its actin-binding region is localized in amino acids 654-676. Its rod-like tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides that is characteristic for -helical coiled coils. Myosin-9 plays a role in cytokinesis, cell shape, secretion, and capping. It is also required for cortical actin clearance prior to oocyte exocytosis. It promotes cell motility in conjunction with A100A4 protein. During cell spreading, myosin-9 is reported to play a role in cytoskeleton reorganization, focal contact formation, and lamellipodial retraction. Genetic variations in MYH9 have been linked with non-diabetic end stage renal disease. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Pazik, J., et al. (2020). BMC Nephrol. 21; Article 380; Li, Z-H., and Bresnick, AR. (2006). Cancer Res. 66(10); 5173-5180).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.